Compare AMAR REMEDIES with LINC PEN &PL - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs LINC PEN & PLASTICS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES LINC PEN & PLASTICS AMAR REMEDIES/
LINC PEN & PLASTICS
 
P/E (TTM) x -0.5 13.4 - View Chart
P/BV x 0.1 2.4 2.5% View Chart
Dividend Yield % 0.0 1.8 -  

Financials

 AMAR REMEDIES   LINC PEN & PLASTICS
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
LINC PEN & PLASTICS
Mar-16
AMAR REMEDIES/
LINC PEN & PLASTICS
5-Yr Chart
Click to enlarge
High Rs164243 67.6%   
Low Rs86136 63.2%   
Sales per share (Unadj.) Rs261.6232.7 112.4%  
Earnings per share (Unadj.) Rs17.412.4 140.4%  
Cash flow per share (Unadj.) Rs22.316.4 135.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs100.768.4 147.3%  
Shares outstanding (eoy) m26.1614.79 176.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.50.8 58.7%   
Avg P/E ratio x7.215.3 47.0%  
P/CF ratio (eoy) x5.611.5 48.6%  
Price / Book Value ratio x1.22.8 44.8%  
Dividend payout %024.2 0.0%   
Avg Mkt Cap Rs m3,2702,800 116.8%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m163186 87.8%   
Avg. sales/employee Rs ThNM5,167.3-  
Avg. wages/employee Rs ThNM278.8-  
Avg. net profit/employee Rs ThNM275.1-  
INCOME DATA
Net Sales Rs m6,8443,441 198.9%  
Other income Rs m217 284.6%   
Total revenues Rs m6,8653,449 199.1%   
Gross profit Rs m1,131314 360.3%  
Depreciation Rs m12860 214.6%   
Interest Rs m39815 2,601.3%   
Profit before tax Rs m626246 254.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m12163 191.5%   
Profit after tax Rs m455183 248.4%  
Gross profit margin %16.59.1 181.2%  
Effective tax rate %19.325.6 75.4%   
Net profit margin %6.65.3 124.9%  
BALANCE SHEET DATA
Current assets Rs m4,9041,334 367.7%   
Current liabilities Rs m3,581802 446.7%   
Net working cap to sales %19.315.5 125.0%  
Current ratio x1.41.7 82.3%  
Inventory Days Days12482 151.6%  
Debtors Days Days10051 197.9%  
Net fixed assets Rs m1,689437 386.2%   
Share capital Rs m262148 177.2%   
"Free" reserves Rs m2,358863 273.1%   
Net worth Rs m2,6351,011 260.6%   
Long term debt Rs m5070-   
Total assets Rs m6,8621,855 370.0%  
Interest coverage x2.617.1 15.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.01.9 53.8%   
Return on assets %12.410.7 116.2%  
Return on equity %17.318.1 95.3%  
Return on capital %31.025.9 119.8%  
Exports to sales %4.027.9 14.3%   
Imports to sales %016.0 0.0%   
Exports (fob) Rs m273959 28.5%   
Imports (cif) Rs mNA552 0.0%   
Fx inflow Rs m273960 28.4%   
Fx outflow Rs m2577 0.3%   
Net fx Rs m271383 70.7%   
CASH FLOW
From Operations Rs m-31397 -322.6%  
From Investments Rs m-489-185 264.5%  
From Financial Activity Rs m76974 1,037.5%  
Net Cashflow Rs m-33-14 236.5%  

Share Holding

Indian Promoters % 25.5 60.4 42.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 9.2 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 39.6 164.9%  
Shareholders   13,061 6,688 195.3%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   JYOTHY LABS  COLGATE  EMAMI LTD  GODREJ INDUSTRIES  HUL  

Compare AMAR REMEDIES With:   P&G (US)  UNILEVER PLC. (UK)  HYPERMARCAS (Brazil)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES - LINC PEN & PLASTICS COMPARISON

COMPARE AMAR REMEDIES WITH

MARKET STATS